Results 11 to 20 of about 15,547 (188)

Machine learning can predict anti-VEGF treatment demand in a Treat-and-Extend regimen for patients with nAMD, DME and RVO associated ME [PDF]

open access: yes, 2021
Purpose: To assess the potential of machine learning to predict low and high treatment demand in real life in patients with nAMD, RVO and DME treated according to a TER. Design: Retrospective cohort study.
Zinkernagel, Martin S.   +8 more
core   +1 more source

NAMD Trajectory of a Tetraoleoyl Cardiolipin Bilayer

open access: yes, 2023
All-atom TOCL (tetraoleoyl cardiolipin) bilayer simulated in NPT ensemble with NAMD and the CHARMM36 force field from Doktorova et al. 2017 Phys. Chem. Chem. Phys. article (DOI 10.1039/c7cp01921a).
Doktorova, Milka
core   +1 more source

SCM-NV/qmflows-namd: Version 0.8.2

open access: yes, 2020
New <ul> <li>Allow computing charge molecules in the <em>C2Pk</em> input.</li> <li>Compute the multipole integrals in the center of mass.</li> <li>A new variable called <code>aux_fix</code> has ...
Prokop   +6 more
core   +1 more source

Grid computing and biomolecular simulation [PDF]

open access: yes, 2005
Biomolecular computer simulations are now widely used not only in an academic setting to understand the fundamental role of molecular dynamics on biological function, but also in the industrial context to assist in drug design.In this paper, two ...
Sansom, Mark   +28 more
core   +1 more source

Differentially Regulated Apolipoproteins and Lipid Profiles as Novel Biomarkers for Polypoidal Choroidal Vasculopathy and Neovascular Age-Related Macular Degeneration

open access: yesFrontiers in Endocrinology, 2022
Lipid dyshomeostasis has been implicated in the pathogenesis of various retinal and choroidal vascular diseases. This study aims to investigate whether apolipoprotein (apo) mediated differential regulation of lipid metabolism contributes to the ...
Xinyuan Zhang   +9 more
doaj   +1 more source

Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data [PDF]

open access: yes, 2021
International audienceAims: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is standard care for neovascular age-related macular degeneration (nAMD), but the recommended monthly injection regimen is burdensome.
Creuzot-Garcher, Catherine   +7 more
core   +1 more source

Clinical Characteristics of Neovascular Age-Related Macular Degeneration without Typical Drusen

open access: yesJournal of Ophthalmology, 2021
Purpose. To evaluate the clinical characteristics of neovascular age-related macular degeneration (nAMD) patients without typical drusen. Methods. We retrospectively studied 165 eyes in 165 patients with treatment-naïve nAMD, including typical AMD and ...
Hiroyuki Kamao   +5 more
doaj   +1 more source

Clinical characteristics and pachychoroid incidence in Japanese patients with neovascular age-related macular degeneration

open access: yesScientific Reports, 2022
The phenotypes of neovascular age-related macular degeneration (nAMD) are recognized as differing between Caucasian and Asian patients. Pachychoroid is thought to be more prevalent in Asians than in Caucasians, and may be involved in the development of ...
Hidetaka Matsumoto   +5 more
doaj   +1 more source

Efficiency of anti-vascular endothelial growth factor drug switch in patients who did not respond to a series of bevacizumab injections

open access: yesIndian Journal of Ophthalmology
Purpose: To assess the effectiveness of switching anti-vascular endothelial growth factor (VEGF) agents in eyes with retinal pathologies that poorly respond to intravitreal bevacizumab injections.
Rotem Gindelskhi Sagiv   +5 more
doaj   +1 more source

qmflows-namd

open access: yes, 2017
<p>QMWorks-NAMD is a generic python library with the purpose of computing (numerically) non-adiabatic coupling vectors (NACV) using several quantum chemical (QM) packages.</p> <p>One of the main problems to calculate (numerically ...
Infante, Ivan (5525420)   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy